Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Melanoma: Optimizing Selection of Adjuvant Therapy

July 18th 2019

Adjuvant Therapy Options in Melanoma Treatment

July 18th 2019

Neoadjuvant Therapy in the Treatment of Melanoma

July 18th 2019

Melanoma: BRAF Status and a Neoadjuvant Therapy Approach

July 18th 2019

Final Thoughts on the Treatment of Breast Cancer

July 16th 2019

Genomic/Somatic Molecular Alteration Evaluation

July 16th 2019

Treatment of Germline BRCA with PARP and Checkpoint

July 16th 2019

The Use of Chemotherapy and Checkpoint Inhibitors for TNBC

July 16th 2019

Immunotherapy for Triple-Negative Breast Cancer

July 16th 2019

Approach to Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 16th 2019

Emerging Agents for Relapsed-Refractory HER2+ MBC

July 16th 2019

Treatment Options for Metastatic HER2+ Breast Cancer

July 16th 2019

Treatment of Homogeneous Tumors vs Heterogenetic Tumors

July 16th 2019

Trials That Shaped HER2-Positive Therapy for BC

July 16th 2019

TAILORx Trial for ER-Positive Patients

July 16th 2019

Implications of Finding Patients With PIK3CA Mutations

July 16th 2019

Treatment After Progression on CDK4/6

July 16th 2019

Predictive and Prognostic Biomarkers and Resistance Mutations

July 16th 2019

MONALEESA-2 and Choosing Among the CDK4/6

July 16th 2019

Introduction and Overview of the MONALEESA-7 Trial

July 16th 2019